Published in Congest Heart Fail on June 10, 2005
Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA (2008) 2.96
Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg (2009) 1.30
Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate? Curr Heart Fail Rep (2013) 1.15
Biocompatibility assessment of the first generation PediaFlow pediatric ventricular assist device. Artif Organs (2011) 1.08
HeartWare miniature axial-flow ventricular assist device: design and initial feasibility test. Tex Heart Inst J (2009) 0.90
Survival benefit of implantable cardioverter-defibrillators in left ventricular assist device-supported heart failure patients. J Card Fail (2011) 0.89
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. Tex Heart Inst J (2008) 0.86
Cardiac rehabilitation and artificial heart devices. J Artif Organs (2009) 0.83
Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant (2007) 0.81
A case of conversion of a NIPRO ventricular assist system to an EVAHEART left ventricular assist system. J Artif Organs (2012) 0.80
Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment. Ont Health Technol Assess Ser (2016) 0.79
Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design. Heart Fail Rev (2008) 0.75
The successful implantation of continuous-flow left ventricular assist device as a destination therapy in Korea: echocardiographic assessment. J Korean Med Sci (2013) 0.75
Development of a Double-Lumen Cannula for a Percutaneous RVAD. ASAIO J (2015) 0.75
Destination therapy: the future is arriving. Congest Heart Fail (2005) 0.75
The Evolution of a Pediatric Ventricular Assist Device Program: The Boston Children's Hospital Experience. Pediatr Cardiol (2017) 0.75
General and acute care surgical procedures in patients with left ventricular assist devices. World J Surg (2014) 0.75
Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med (2001) 18.91
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Concern Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet (2011) 11.45
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med (2007) 7.15
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Multicenter bridge to transplantation with the HeartMate assist device: evaluation from another perspective. A rebuttal. J Thorac Cardiovasc Surg (2003) 5.03
Sinus of Valsalva aneurysm or fistula: management and outcome. Ann Thorac Surg (1999) 4.78
Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation (2007) 4.67
Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med (2010) 4.31
The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank (2008) 4.13
Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging (2011) 3.83
Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J (2004) 3.70
Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol (2010) 3.63
Primary cardiac sarcomas. Ann Thorac Surg (1991) 3.61
Salvage of infected left ventricular assist device with antibiotic beads. Plast Reconstr Surg (2014) 3.28
Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation (2012) 3.24
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol (2013) 2.92
Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation (2012) 2.83
Prolonged QTc interval and high B-type natriuretic peptide levels together predict mortality in patients with advanced heart failure. Circulation (2003) 2.75
The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant (2013) 2.71
The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant (2010) 2.59
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Metabolic gene expression in fetal and failing human heart. Circulation (2001) 2.59
Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol (2012) 2.37
Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med (2012) 2.36
Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation (2007) 2.34
Surgical treatment of cardiac tumors: a 25-year experience. Ann Thorac Surg (1990) 2.34
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting. Ann Thorac Surg (1989) 2.17
Preoperative hematocrit is a powerful predictor of adverse outcomes in coronary artery bypass graft surgery: a report from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg (2013) 2.15
Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation (2002) 2.15
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Usefulness of routine periodic fasting to lower risk of coronary artery disease in patients undergoing coronary angiography. Am J Cardiol (2008) 2.10
Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg (2012) 2.10
Device-supported myocardial revascularization: safe help for sick hearts. Ann Thorac Surg (1992) 2.06
Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on Heart Failure Research. Circulation (1997) 2.00
Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail (2011) 1.99
Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med (2007) 1.98
HeartWare ventricular assist device placement in a patient with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg (2012) 1.96
Complete resection of a right atrial intracavitary metastatic melanoma. Ann Thorac Surg (1996) 1.95
Effects of the 2006 U.S. thoracic organ allocation change: analysis of local impact on organ procurement and heart transplantation. J Heart Lung Transplant (2009) 1.91
Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail (2012) 1.90
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics (2006) 1.88
Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta (2011) 1.83
Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol (2010) 1.81
Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. Circ Heart Fail (2009) 1.77
Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail (2010) 1.75
Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation (2013) 1.73
A micro-ribonucleic acid signature associated with recovery from assist device support in 2 groups of patients with severe heart failure. J Am Coll Cardiol (2011) 1.71
Coronary artery bypass for unsuccessful percutaneous transluminal coronary angioplasty. J Thorac Cardiovasc Surg (1984) 1.71
Dispatcher-assisted cardiopulmonary resuscitation: risks for patients not in cardiac arrest. Circulation (2009) 1.71
Extension of donor criteria in cardiac transplantation: surgical risk versus supply-side economics. Ann Thorac Surg (1990) 1.69
First permanent implant of the Jarvik 2000 Heart. Lancet (2000) 1.68
Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med (2009) 1.67
Transmission of retroviruses by transfusion of screened blood in patients undergoing cardiac surgery. N Engl J Med (1989) 1.67
The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med (2008) 1.66
Bedside right ventricular assist device removal in the conscious patient. Ann Thorac Surg (2007) 1.63
Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant (2009) 1.62
End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices. J Heart Lung Transplant (2007) 1.60
Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging (2008) 1.60
Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis (2006) 1.58
Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation (2012) 1.57
Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg (2010) 1.57
Bacterial mediastinitis after heart transplantation. J Heart Lung Transplant (1992) 1.56
Defining pulsatility during continuous-flow ventricular assist device support. J Heart Lung Transplant (2013) 1.55
Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg (2004) 1.54
Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device. Ann Thorac Surg (2008) 1.54
Flail tricuspid leaflet after multiple biopsies following orthotopic heart transplantation: echocardiographic and hemodynamic correlation. J Heart Lung Transplant (1994) 1.52
Predictors of stroke in patients paced for sick sinus syndrome. J Am Coll Cardiol (2004) 1.52
Evaluation of myocardial function in patients with end-stage heart failure during support with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant (2005) 1.51
Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS One (2009) 1.49
Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J (2005) 1.49
Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant (2005) 1.48
Destination therapy: one-year outcomes in patients with a body mass index greater than 30. Artif Organs (2009) 1.48
Bloodless Orthotopic Heart Transplantation in a Jehovah's Witness. A A Case Rep (2015) 1.47
Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant (2005) 1.47
Atrial fibrillation after cardiac transplantation: experience in 498 consecutive cases. Ann Thorac Surg (2008) 1.46
A novel subcutaneous counterpulsation device: acute hemodynamic efficacy during pharmacologically induced hypertension, hypotension, and heart failure. Artif Organs (2010) 1.46
Patent foramen ovale: a cause of hypoxemia in patients on left ventricular support. Ann Thorac Surg (1991) 1.45
Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death? J Heart Lung Transplant (2010) 1.44
Cardiac tumors. Clinical spectrum and prognosis of lesions other than classical benign myxoma in 20 patients. J Thorac Cardiovasc Surg (1984) 1.43
Low-dose prophylactic intravenous immunoglobulin does not prevent HLA sensitization in left ventricular assist device recipients. Ann Thorac Surg (2006) 1.43
Effect of ABO-incompatible listing on infant heart transplant waitlist outcomes: analysis of the United Network for Organ Sharing (UNOS) database. J Heart Lung Transplant (2009) 1.42
Effect of pump flow mode of novel left ventricular assist device upon end organ perfusion in dogs with doxorubicin induced heart failure. ASAIO J (2005) 1.41
Pump replacement for left ventricular assist device failure can be done safely and is associated with low mortality. Ann Thorac Surg (2012) 1.41
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
Thrombogenicity of mechanical aortic valves in an animal model: site specific testing is crucial. ASAIO J (2004) 1.39
TandemHeart as a rescue therapy for patients with critical aortic valve stenosis. Ann Thorac Surg (2009) 1.39
Lung cancer after heart transplantation: a 17-year experience. Ann Thorac Surg (2005) 1.39